Eli Lilly Says Amyvid Now Available in Select US Markets; Forest Labs and Nabriva Sign Agreement Print E-mail
By Staff and Wire Reports   
Friday, 01 June 2012 21:28
Below is a look at some of the headlines for companies that made news in the healthcare sector on June 1, 2012.

Eli Lilly and Company (NYSE: LLY)
and Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Lilly, today announced that Amyvid is available to imaging centers in markets surrounding 16 manufacturing sites located in Atlanta; Charlotte, N.C.; Chicago; Colton, Calif; Columbus, Ohio; Dallas; Fort Lauderdale, Fla.; Hartford, Conn.; Houston; Jacksonville, Fla.; North Wales, Pa.; Orlando, Fla.; Palo Alto, Calif.; Phoenix; Seattle; and St. Louis.


Forest Laboratories (NYSE:FRX)
and Nabriva Therapeutics announced they have entered into an agreement for the development of Nabriva's novel antibacterial agent, BC-3781. Pursuant to the agreement, Forest will provide Nabriva with $25 million, and fund and conduct in collaboration with Nabriva, certain development activities related to BC-3781 over the next 12 months. During the 12-month period, Forest has the exclusive right to acquire Nabriva.

Forest's decision to acquire Nabriva will be dependent upon certain contingencies. No further financial or other terms were disclosed. The transaction is subject to customary regulatory clearances including termination of the applicable Hart-Scott-Rodino waiting period. Citi and WilmerHale acted as advisors to Nabriva in regards to this transaction

Also Friday:

Anacor Pharmaceuticals (NASDAQ:ANAC)
announced today the appointment of Paul L. Berns to its Board of Directors. Since 2006, Mr. Berns has served as the President, Chief Executive Officer, and a member of the Board of Directors of Allos Therapeutics, a biopharmaceutical company focused on developing and commercializing anti-cancer therapeutics.

Biogen Idec Inc. (NASDAQ: BIIB)
announced today that its 2012 Annual Shareholders Meeting will be webcast live on Friday, June 8, 2012 at 9:00 a.m. ET.

BioLife Solutions, Inc. (OTCBB: BLFS)
, a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract media manufacturer, today announced that it has executed an amendment to its longstanding term loan facility with the current investment group that is also represented on the Company's Board of Directors.

Biostem U.S., Corporation (OTCQB: HAIR) (PINKSHEETS: HAIR)
(Biostem, the Company), a fully reporting public company in the stem cell regenerative medicine science sector, has made its Scientific and Medical Board of Advisors publications available on the company website, www.biostemus.com.

Scientists from United BioSource Corporation (UBC), a wholly-owned subsidiary of Express Scripts Holding Company (NASDAQ: ESRX), will be presenting data at the 17th Annual International Society for Pharmacoeconomics and Outcomes Research (ISPOR) meeting June 2-6 in Washington, D.C.

IDEXX Laboratories, Inc. (NASDAQ: IDXX)
, announced today that it will participate in the William Blair 32nd Annual Growth Stock Conference.

IDEXX Laboratories, Inc. (NASDAQ: IDXX)
, announced today that it will participate in the William Blair 32nd Annual Growth Stock Conference. Jonathan Ayers, Chairman and CEO, is scheduled to make a presentation on the Company on Tuesday, June 12, 2012 at 8:10 a.m. (Central Time), at the Four Seasons Hotel, Chicago, Illinois.

Life Technologies Corporation (NASDAQ: LIFE)
will exhibit platforms for companion diagnostic development and products ideal for basic, translational and clinical cancer research during the American Society for Clinical Oncology (ASCO) Annual Meeting 2012, taking place June 1 – June 5, in Chicago, Illinois.

NPS Pharmaceuticals, Inc. (NASDAQ: NPSP)
, a specialty pharmaceutical company developing orphan therapeutics for rare gastrointestinal and endocrine disorders, today announced its support for World Hypoparathyroidism Awareness Day.

Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR)
today announced that the Company will present at the Jefferies 2012 Global Healthcare Conference on Wednesday, June 6 at 9:00 a.m. Eastern Time in New York, NY.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA)
announced that Dr. Phillip Frost, Chairman of the Board of Directors, purchased one million Teva American Depositary Shares on Wednesday, May 30, 2012, the first day of trading on the New York Stock Exchange, at prices ranging from $37.82 to $39.57.

Walgreens (NYSE: WAG) (NASDAQ: WAG)
today issued the following statement about a dispute with Express Scripts, Inc. filed in September 2011:  “The parties have agreed to dismiss their respective claims, and no other action has been or will be taken by either party with respect to this case.

"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus